Company intelligence / Profile preview

Luxena Pharmaceuticals

San Diego, California, United Statesluxenapharma.com ↗

Ownership: Private
Development stage: Other

Overview

Luxena Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of various cancers. The company's lead candidate, LX-101, is a potent and selective inhibitor of PIM kinases (PIM-1, PIM-2, and PIM-3), which are known to play a critical role in cell survival and proliferation in hematologic malignancies and solid tumors. Luxena is currently evaluating LX-101 in Phase 1/2 clinical trials for patients with relapsed or refractory chronic lymphocytic leukemia and other B-cell malignancies. The company aims to address unmet medical needs by targeting pathways that drive resistance to current standard-of-care therapies.

Therapeutic areas: OncologyHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

LPI-1503

Beyond the preview

Go deeper on Luxena Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luxena Pharmaceuticals.